Compare Crocs, Inc. (CROX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Incyte Corporation — how do they compare? Crocs, Inc. trades at $129.26 (market cap $6.31B), while Incyte Corporation trades at $120.7 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.9× Crocs, Inc.'s market cap. Which is the better fit depends on your goals.
| CROX | INCY | |
|---|---|---|
Market Cap | $6.31B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $129.93 |
52-Week Low | $73.39 | $81.61 |
Enterprise Value | $7.83B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $138.19, up 1.15% today, near its 52-week high. The stock shows bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $4.55 versus $4.35 expected. Revenue trends are stable around $4B annually, though 2025 net income was negative due to high taxes. Analysts maintain a buy-heavy consensus with a $140.43 price target.
Outlook is positive with robust profitability margins and valuation support, but risks include tax scrutiny from recent Malta office news and HEYDUDE brand weakness. The stock offers growth potential if execution improves, yet investors face volatility from guidance misses and competitive pressures.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
